Predictive Value of C–reactive Protein, Lactate Dehydrogenase, Ferritin and D-dimer Levels in Diagnosing COVID-19 Patients: a Retrospective Study

Ahmed N. Kaftan¹, Majid K. Hussain¹, Abdulhussein A. Algenabi¹, Farah H. Naser², Muslim A. Enaya²

¹Biochemistry Department, Faculty of Medicine, Kufa University, Najaf, Iraq
²Najaf Health Directorate, Najaf, Iraq

Corresponding author: Ahmed Naseer Kaftan. Biochemistry Department, Faculty of Medicine, Kufa University, Najaf, Iraq, E-mail: Ahmedn. kaftan@uokufa.edu.iq, Ahmedn.kaftan@uokufa.edu.iq

doi: 10.5455/aim.2021.29.45-50
ACTA INFORM MED. 2021 MAR 29(1): 45-50
Received:  Feb 07, 2021
Accepted:  Mar 20, 2021

© 2021 Ahmed N. Kaftan, Majid K. Hussain, Abdulhussein A. Algenabi, Farah H. Naser, Muslim A. Enaya
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Background: Since December 2019, millions of people in the world have been affected with the novel Coronavirus disease-2019 (COVID-19) pandemic, and high economic impact has affect many countries especially low socioeconomic one like Iraq due to the high cost and limited availability of RT-PCR for diagnosis of COVID-19, so there should be predictive low cost easily available laboratory tests that can be used before proceeding to the high cost techniques. Objective: In this retrospective study we aimed to evaluate the diagnostic accuracy of CRP, ferritin, LDH and D-dimer in predicting positive cases of COVID-19 in Iraq. Methods: It is a retrospective observational cohort study based on STARD guidelines to determine the diagnostic accuracy of (CRP, LDH, ferritin and D dimer) for COVID-19 of electronic medical records of private medical center in Najaf city, at which 566 individuals were recruited. The investigated subjects were either in close contact with previously COVID-19 positive patients or have one or more symptoms of COVID-19. They were categorized into 2 groups, 205 subjects diagnosed with RT-PCR as COVID-19 negative, and 361 COVID-19 positive patients, results of study variables of the cohort were recruited from the medical records. Results: Combining of these parameters had the following findings: CRP + ferritin; AUC: 0.77 with 55% sensitivity and 97% specificity, Ferritin + LDH; AUC: 0.83 with 65% sensitivity and 92% specificity, CRP+LDH; AUC: 0.78 with 56% sensitivity and 98% specificity, CRP + LDH + ferritin; AUC: 0.85, with 73% sensitivity and 88% specificity, CRP + LDH + ferritin + D dimer; AUC: 0.85 75% sensitivity and 87% specificity. Conclusion: Combination of routine laboratory biomarkers (CRP, LDH and ferritin ±D dimer) can be used to predict the diagnosis of COVID-19 with an accepted sensitivity and specificity before proceeding to definitive diagnosis by RT-PCR.

Keywords: COVID-19, CRP, LDH, ferritin and D-dimer.

1. BACKGROUND

In December 2019 an acute respiratory disease known as the novel coronavirus infection (COVID-19) has appeared in the city of Wuhan, Hubei Province, China since December 2019. It is manifested as an acute respiratory disease, promptly spreading globally (1). The World Health Organization (WHO) has declared on January 2020 the outbreak of COVID-19 as a global pandemic and a Public Health Emergency of International Concern (PHEIC).

Till January 12, 2021, the confirmed cases of COVID-19 reached above 90.000.000 with more than 1.900.000 deaths (2). Iraq is one of the top ranking countries affected by COVID-19 with more than 600.000 confirmed cases and more than 12.000 death (2).

The clinical presentation of the disease is highly variable, ranging from asymptomatic or only mild symptoms (80%), to severe multi organ failure and even death. Symptoms include fever, loss of sense of smell and or taste, sore throat, shortness of breath, non-productive cough, general fatigue, myalgia, and headache. Some patients (15-20%) may develop acute respiratory distress syndrome (ARDS), and in some cases kidney and heart failure (3-5). COVID-19 had a similar clinical course and patho-
logical findings with the Severe Acute Respiratory Syndrome (SARS) and the Middle East Respiratory Syndrome (MERS) due to the genetic homologies between coronaviruses (6). Severe states of COVID-19 cause a hyper inflammatory response, leading to a pathological dysfunction of innate host defense mechanisms, causing complications like multiple organ failure and or cytokine release syndrome (cytokine storm) (7). C-reactive protein (CRP) is an acute-phase protein appears in blood within 6–10 hours of any tissue damaging event and has a plasma half-life of 19 hours, its synthesized by the liver when the body is affected by inflammation, such as bacterial or viral infection or tissue destruction (8).

Ferritin is an iron storage form; it is one of the biomarkers of inflammation. In bacterial or viral infection, an increase in ferritin occurs due to iron release in the endoplasmic reticulum and to a decline in its transport capacity due to spleen and liver damage (9). Lactate dehydrogenase (LDH) is an enzyme involved in glycolysis, catalyzes pyruvate to lactate conversion and present in all tissues. It is released from cells upon damage of their cytoplasmic membrane by for example viral infection (10). D-dimers are multiple peptide fragments synthesized as a result of cross linked fibrin degradation mediated by plasmin. Its level would elevate in any process that involves production and breakdown of fibrin, such as acute infections, surgery and acute or chronic inflammatory states (11).

COVID-19 has been reported to be associated with coagulopathy and 3.75–68.0% of the COVID-19 patients have been found to have raised D-dimer levels (12, 13). Till now no FDA-approved therapeutics for COVID-19 were registered. Thus, the continuous seeking for markers associated with the course of the disease can aid to better diagnostic accuracy, probably may also explore the severity of the disease. Such attempts may help clinical decision-making and reduction of the use of high cost techniques for diagnosis such as RT-PCR and CT scanning. Despite the increasing number of studies on COVID-19 in the last months, there are limited data on laboratory features of COVID-19 cases in Arab populations especially Iraq.

2. OBJECTIVE

In this retrospective study we aimed to evaluate the diagnostic accuracy of CRP, ferritin, LDH and D-dimer in predicting positive cases of COVID-19 in Iraq.

3. METHODS

Study design

It is a retrospective observational cohort study based on STARD guidelines to determine the diagnostic accuracy of (CRP, LDH, ferritin and D dimer) for COVID-19 of electronic medical records at a private medical center in Najaf city. Najaf is a large city lie in the south of Iraq, and as a part of the screening program for COVID-19 adapted by the Ministry of health (MOH), hundreds of tests has been done each day for COVID-19 through a RT-PCR of nasopharyngeal swabs at the Central Laboratory of MOH in Najaf city. The diagnosis of COVID-19 was based on WHO guidelines (14).

Many of these individuals presents to outpatient private medical center at Najaf city for consultation.

Study subjects

Sample size was based on minimum sensitivity and specificity of 95%, we randomly selected medical records of 938 subjects suspected to have COVID-between May and December 2020.

Inclusion criteria

Men and women aged (30-70 y), They were either in close contact with previously COVID-19 confirmed positive patients or have one or more symptoms of COVID-19 such as: fever, cough, sore throat, dyspnea, muscle aches and loss of smell or taste. 566 subjects were divided into two groups. Group one consisted of 205 individuals who have COVID-19 negative result and group two comprised of 361 patients who have positive COVID-19 result.

Exclusion criteria

Individuals of incomplete laboratory records or has medical history of renal failure, liver failure, diabetes mellitus, hypertension, active tumor, active infection, pregnant women and children, 372 subjects were excluded.

Study variables

The index test for diagnosis of COVID-19 was RT-PCR for detection of viral RNA in nasopharyngeal swab this test was used according to WHO guidelines for diagnosis of COVID-19 and it’s done by governmental center (Central Laboratory of MOH in Najaf). The laboratory records that have been recruited from study individuals included: CRP, ferritin, LDH and D dimer. CRP level was measured by latex enhanced immunoturbidimetric method using VIDAS (Bio Mérieux, Marcy L’Etoile, France). Ferritin was assessed by electro-Chemiluminescence immune method using Cobas Roche e411 auto analyzer (Roche Diagnostics GmbH, Mannheim, Germany). The study was approved by the Ethical committee at Kufa University. Informed consent was obtained from participants after elaborating the plan of the study.

Statistical analysis

Statistical analyses have carried out by using the IBM-SPSS statistics software (version 25; IBM, New York, USA). Shapiro-Wilk test has been used to test for normality of data, Numerical variables were displayed as median with inter-quartile range (IQR). Categorical variables have been tested by the Mann-Whitney U test. The association of independent variables among groups has been evaluated at the use of univariate and multivariate logistic regressions. The odds ratio (OR) with 95% confidence interval (95%CI) has been estimated. Spearman’s correlation analysis has been applied to determine the variable correlations. Receiver operating characteristic (ROC) analysis was used to assess the sensitivity and specificity of each parameter and of combined parameters through the area under the curve (AUC). Youden index has been applied to determine the cutoff value of each diagnostic
Predictive Value of C-reactive Protein, Lactate Dehydrogenase, Ferritin and D-dimer Levels in Diagnosing COVID-19 Patients: a Retrospective Study

4. RESULTS

Figure 1 shows the flow chart of study participants and Table 1 shows the demographic characteristics of the study persons. The total analyzed persons were 566; their age’s median was 49 y with a range of 30-70 y. There were 292 (51.6%) males and 274 (48.4%) females. Those of COVID-19 negative RT-PCR outcomes (Group 1) were 205 (36.2%) while those of COVID-19 positive results (Group 2) were 361 (63.8%). No significant differences were indicated for gender and ages among the 2 groups. Table 2 shows the comparison of the median values of laboratory parameters in the 2 study groups using Mann Whitney test. Significant (P: <0.01, OR: 1.005, P: <0.01, OR: 1.02, P: <0.01 respectively) associated with the increased risk for COVID-19 infection. The correlation analysis highlights significant positive correlation of CRP with ferritin levels (r: 0.4, P: <0.01) and CRP with D-dimer levels (r: 0.3, P: <0.01) (Table 4). The ROC curve analysis (Figure 2) illustrates a cutoff value for CRP of 14.5 mg/L, with an AUC value of 0.7, the sensitivity and specificity were 50% and 77% respectively. Ferritin cutoff value was found to be 290 ng / ml and the AUC was 0.7 with sensitivity and a specificity of 49% and 96% respectively. LDH cutoff value was determined to be 278 UL and the AUC value was 0.6 with sensitivity and a specificity of 0.3.

Table 1. Demographic characteristics of study subjects

| Parameter                  | N=205 (36.2%) | N=361 (63.8%) | P value |
|----------------------------|---------------|---------------|---------|
| Age (y)                    | 49 (20)       | 48 (22)       | 0.77    |
| CRP (mg/L)                 | 6 (9)         | 18 (46)       | < 0.001 |
| Ferritin (ng/mL)           | 96 (139)      | 281 (1996)    | < 0.001 |
| LDH (U/L)                  | 230 (54)      | 257 (74)      | < 0.001 |
| D-dimer (mg/L)             | 0.2 (0.3)     | 0.3 (0.8)     | 0.03    |

Table 2. Median comparison of laboratory parameters between study subjects using Mann Whitney test. All data expressed as median (IQR). P value < 0.05 considered statistically significant. OR: inter quartile range test. P values of less than 0.05 were considered statistically significant.

Table 3. ROC curve analysis of the laboratory parameters in predicting positive COVID-19 cases. ROC: receiver operating characteristics. AUC: area under the curve. P value < 0.05 is considered statistically significant

| Parameter                  | Cut off value | Youden index | AUC | 95% CI | P value | Sensitivity | Specificity |
|----------------------------|---------------|--------------|-----|--------|---------|-------------|-------------|
| CRP (mg/L)                 | 14.5          | 0.33         | 0.67 | 0.75   | < 0.001 | 0.56        | 0.77        |
| Ferritin (ng/mL)           | 290           | 0.46         | 0.69 | 0.77   | < 0.001 | 0.49        | 0.96        |
| LDH (U/L)                  | 278           | 0.31         | 0.65 | 0.73   | < 0.001 | 0.38        | 0.93        |
| D-dimer (mg/L)             | 0.5           | 0.15         | 0.51 | 0.61   | < 0.001 | 0.30        | 0.84        |

Table 4. Correlation analysis of laboratory parameters in the 2 investigated groups. r: correlation coefficient. P value < 0.05 is considered statistically significant

| Parameter                  | Age | CRP (mg/L) | Ferritin (ng/mL) | LDH (U/L) | D-dimer (mg/L) |
|----------------------------|-----|------------|------------------|-----------|----------------|
| CRP (mg/L)                 | 1.005 | (-0.02) | 0.66 | 0.07 | 0.02 | 0.76 |
| Ferritin (ng/mL)           | (-0.04) | 0.27 | (0.45) | < 0.001 |
| LDH (U/L)                  | -0.01 | 0.66 | (0.07) | 0.09 | 0.02 | (-0.01) | 0.76 |
| D-dimer (mg/L)             | -0.01 | 0.68 | (0.32) | < 0.001 | (0.07) | 0.06 |

Table 5. ROC curve analysis of combined parameters in predicting positive COVID-19 cases. ROC: receiver operating characteristics. AUC: area under the curve. P value < 0.05 is considered statistically significant

| Parameter                  | Cut off value | Youden index | AUC | 95% CI | P value | Sensitivity | Specificity |
|----------------------------|---------------|--------------|-----|--------|---------|-------------|-------------|
| CRP + ferritin             | 0.53          | 0.77         | 0.74 | 0.81   | < 0.001 | 55          | 97          |
| Ferritin + LDH             | 0.53          | 0.83         | 0.80 | 0.86   | < 0.001 | 65          | 92          |
| CRP + LDH                  | 0.46          | 0.78         | 0.75 | 0.82   | < 0.001 | 56          | 98          |
| CRP + LDH + ferritin       | 0.61          | 0.85         | 0.82 | 0.88   | < 0.001 | 73          | 88          |
| CRP + LDH + ferritin + D-dimer | 0.62     | 0.85 | 0.82 | 0.88 | < 0.001 | 75          | 87          |
The pandemic of COVID-19 has become a global catastrophe, characterized with elevated rate of complications and mortality and even economic impact. Thus, an urgent need is essential for cost effective and convenient diagnostic tools to predict the diagnosis of COVID-19 before proceeding to the high cost techniques, and combining multiple markers to predict the diagnosis of COVID-19.

Our findings of CRP, LDH, ferritin and D-dimer levels revealed significant increases in those who were tested COVID-19 positive with RT-PCR when compared with those who were tested negative. A previous study in Italy (20) reported that CRP and LDH are significantly increased in those who were COVID-19 positive and these tests could be used as alternatives to RT-PCR for identifying COVID-19-positive patients. Another studies reported that CRP, LDH, ferritin and D-dimer were used to evaluate the severity of the disease and a high level are associated with poor outcome and mortality (21, 22).

Results of the multivariate logistic regression analysis have explored that CRP, LDH and ferritin are associated with increased risk of COVID-19 infection while, D-dimer did not do so, possibly because most of the cases that included in the study are outpatients without severe presentations. A recent metaanalysis (23) demonstrated that high levels of CRP, ferritin and D-dimer are associated with poor outcome in COVID-19. Spearman correlation analysis showed that CRP and ferritin were positively correlated, this finding also reported by Lui et al (22). The specificity and sensitivity of CRP, LDH, ferritin and D-dimer estimations in suspected COVID-19 patients have been determined with the ROC method, the cutoff value for each marker in predicting the presence of COVID-19 infection has also been estimated.

The AUC for CRP, LDH and ferritin were about 0.7. Mardani et al. (24) reported an AUC of 0.8 for CRP and LDH which equals to our result (0.7). We found that ferritin and LDH had the highest specificity among these parameters (0.96 and 0.93 respectively) but unfortunately low sensitivity (0.49 and 0.38 respectively). We determined a cutoff value of 290 ng/mL for ferritin, a close value (304 ng/mL) was reported by Tular Onur et al. (25). For LDH, our cutoff value was found to be 278 mg/dL, this value was similar to the result (277 mg/dL) reported by Li et al. (26). For CRP, a cutoff value of 14 mg/L was observed to be concomitant with a specificity of 0.77 and a sensitivity of 0.56, these findings in line with those reported by Cheng et al. (27).

Although there is no general agreement on a cutoff value to determine the severity of COVID-19, a recent meta-analysis (23) has shown that the majority of studies suggested a value of ≥10 mg/L cutoff for CRP and 0.5 mg/L for D-dimer. CRP may not only be used as a prognostic marker, but also to monitor the disease improvement (23). COVID-19 patients with markedly increased D-dimer levels may require hospitalization, despite the severity of clinical presentation (28-38). The diagnosis of COVID-19 depends on high cost techniques like RT-PCR and CT imaging.

However, in a country like Iraq with a high rate of poverty and limited medical resources we can consider these routine low cost and available laboratory tests (CRP, LDH and ferritin) to predict the diagnosis of COVID-19 before proceeding to the high cost techniques, and combination of these markers cause improvement in sensitivity of analysis, so combination of (CRP, LDH and ferritin ± D dimer).

5. DISCUSSION

The pandemic of COVID-19 has become a global catastrophe, characterized with elevated rate of complications and mortality and even economic impact. Thus, an urgent need is essential for cost effective and convenient indicators to simplify the diagnostic process and evaluate the disease severity. Numerous studies have identified raised levels of several serum or plasma biochemical constituents, including inflammatory parameters in COVID-19 patients (15-17). In SARS and MERS patients, elevated serum-pro-inflammatory cytokines has been reported in severe conditions compared to the mild and moderate cases (18, 19).

In our study, we pursed to assess the diagnostic accuracy of certain laboratory biomarkers (CRP, LDH, ferritin and D-dimer) in diagnosing of COVID-19 cases. It’s one of the first studies that describe these findings in Arab population especially Iraq and the first one that uses combined markers to predict the diagnosis of COVID-19.

Our findings of CRP, LDH, ferritin and D-dimer levels revealed significant increases in those who were tested COVID-19 positive with RT-PCR when compared with those who were tested negative. A previous study in Italy (20) reported that CRP and LDH are significantly increased in those who were COVID-19 positive and these tests could be used as alternatives to RT-PCR for identifying COVID-19-positive patients. Another studies reported that CRP, LDH, ferritin and D-dimer were used to evaluate the severity of the disease and a high level are associated with poor outcome and mortality (21, 22).

Results of the multivariate logistic regression analysis have explored that CRP, LDH and ferritin are associated with increased risk of COVID-19 infection while, D-dimer did not do so, possibly because most of the cases that included in the study are outpatients without severe presentations. A recent metaanalysis (23) demonstrated that high levels of CRP, ferritin and D-dimer are associated with poor outcome in COVID-19. Spearman correlation analysis showed that CRP and ferritin were positively correlated, this finding also reported by Lui et al (22). The specificity and sensitivity of CRP, LDH, ferritin and D-dimer estimations in suspected COVID-19 patients have been determined with the ROC method, the cutoff value for each marker in predicting the presence of COVID-19 infection has also been estimated.
Limitation of the study

It is useful to mention the limitations of the current study. First, hospitalized patients were not recruited in the present investigation. Second, the severity of the disease was undefined in relevance to the laboratory parameter changes; third, we not include other laboratory markers such as procalcitonin, interleukins and hematological markers.

6. CONCLUSION

Combination of routine laboratory biomarkers (CRP, LDH and ferritin ±D dimer) can be used to predict the diagnosis of COVID-19 with an accepted sensitivity and specificity before proceeding to definitive diagnosis by RT-PCR.

ethics:
• Ethical approval: This study was conducted according to the World Medical Association Declaration of Helsinki. It’s approved by the Ethical committee at Kufa University. Informed consent was obtained from participants after elaborating the plan of the study.
• Author’s contribution: Material preparation, data collection, and analysis were performed by A.N.K. who is the co-corresponding author. F.H.N written the first draft of the manuscript and also helped to revise the manuscript. M.K.H designed the study, and took responsibility for the integrity of data and the accuracy of data analysis; A.A.A provided the administrative, technical and material support; All authors read and approved the final manuscript.
• Conflicts of interest: The authors declare that they have no conflicts of interest.
• Financial support and sponsorship: None.

REFERENCES

1. Hong H, Wang Y, Chung HT, Chen CJ. Clinical characteristics of novel coronavirus disease 2019 (COVID-19) in newborns, infants and children. Pediatr Neonatol. 2020 Apr; 61(2): 131-132. doi: 10.1016/j.pedneo.2020.03.001.
2. Chen YC, Cao Q, Chen CL, Chiu CH. Reply to letter to the editor: Kawasaki disease and COVID-19: A pretext for a hot topic. J Formos Med Assoc. 2021 Jan 8; S0929-6646, (21)00003-6. doi: 10.1016/j.jfma.2021.01.001. Online ahead of print. PMID: 33431260.
3. Kluge S, Janssens U, Welte T, Carstens SW, Marx G, Karagiannis C. Recommendations for critically ill patients with COVID-19. Med Klin Intensivmed Notfmed. 2020. 115(3): 175-177. doi: 10.1007/s00063-020-00674-3.
4. Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease Control and Prevention. The epidemiological characteristics of an outbreak of 2019 novel coronavirus disease (COVID-19) in China. Zhonghua Liu Xing Bing Xue Za Zhi. 2020. 41(2): 145-151. doi: 10.3760/cma.j.isn.0254-6450.2020.02.003.
5. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020. 382(18): 1708-1720. doi: 10.1056/NEJMoa2002032.
6. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020. 395(10223): 497-506. doi: 10.1016/S0140-6736(20)30183-5.
7. Potempa LA, Rajab IM, Hart PC, Bordon J, Botran RF. Insights into the Use of C-Reactive Protein as a Diagnostic Index of Disease Severity in COVID-19 Infections. Am J Trop Med Hyg. 2020, 103(2): 561-563. doi: 10.4269/ajtmh.20-0473.
8. Black S, Kushner I, Samols D. C–reactive protein. J Biol Chem. 2004. 279(47): 48487-48490. doi: 10.1074/jbc.R400025200.
9. Mackay AD, Marchant ED, Munk DJ, Watt EK, Hansen JM, Thomson DM, Hancock CR. Multitissue analysis of exercise and metformin on doxorubicin-induced iron dysregulation. Am J Physiol Endocrinol Metab. 2019, 316(5): E922-E930. doi: 10.1152/ajpendo.00140.2018.
10. Yousif NG, Altimimi AN, Al-amran FG, Adrienne J, Al-Fadhil SM, Hussien SR. et al. Hematological changes among Coronavirus virus-19 patients: a longitudinal study. Sys Rev Pharm 2020; 11(5): 862-866. doi: 10.31838/srp.2020.5.125.
11. Thachil J, Lippi G, Favaloro EJ. D-Dimer Testing: Laboratory Aspects and Current Issues. Methods Mol Biol. 2017; 1646: 91-104. doi: 10.1007/978-1-4939-7196-1_7.
12. Wu J, Liu J, Zhao X, Liu C, Wang W, Wang D, et al. Clinical Characteristics of Imported Cases of Coronavirus Disease 2019 (COVID-19) in Jiangsu Province: A Multicenter Descriptive Study. Clin Infect Dis. 2020 Jul 28; 71(15): 706-712. doi: 10.1093/cid/ciaa199.
13. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020. 395(10229): 1054-1062. https://doi.org/10.1016/S0140-6736(20)30566-3.
14. WHO. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected” on 13 March 2020. WHO/2019-nCoV/capacities/2020.5, accessed 23 November 2020.
15. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H. et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020; 323(11): 1061-1069. doi: 10.1001/jama.2020.1585.
16. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, Xie C, Ma K, Shang K, Wang W, Tian DS. Dysregulation of Immune Response in Patients with Coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 2020 Jul 28; 71(15): 762-768. doi: 10.1093/cid/ciaa248.
17. Gao Y, Li T, Han M, Li X, Wu D, Xu Y, Zhu Y, Liu Y, Wang X, Wang L. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. J Med Virol. 2020 Jul 9; 92(7): 791-796. doi: 10.1002/jmv.25770.
18. Min CK, Cheon S, Ha NY, Sohn KM, Kim Y, Algerin A, Shin HM, et al. Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity. Sci Rep. 2016; Article number: 25359.
19. Yousif NG. Fibronectin promotes migration and invasion of ovarian cancer cells through up-regulation of FAK–PI 3 K/Akt pathway. Am J Physiol Endocrinol Metab. 2019, 316(5): E922-E930.
20. Ferrari D, Motta A, Strollo M, Banfi G, Locatelli M. Routine blood tests as a potential diagnostic tool for COVID-19. Clin Chem Lab Med. 2020 Jun 25; 58(7): 1095-1099. doi: 10.1515/cclm-2020-0398.
21. Pan F, Yang L, Li Y, Liang B, Li L, Yu T, Li L, Liu D, Gui S, Hu Y, Zheng C. Factors associated with death outcome in patients with severe coronavirus disease-19 (COVID-19): a case-control study. Int J Med Sci. 2020. 17(9): 1281-1292. doi: 10.7150/
22. Liu SL, Wang SY, Sun YF, Jia QY, Yang CL, Cai PJ, Li JJ, Wang L, Chen Y. Expressions of SAA, CRP, and FERR in different severities of COVID-19. European Review for Medical and Pharmacological Sciences, 01 Nov 2020, 24(21): 11386-11394. doi: 10.26355/eurrev_202011_23631.

23. Huang I, Pranata R, Lim MA, Oehadian A, Alisjahba-na B. C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis. Ther Adv Respir Dis. 2020 Jan-Dec; 14: 1753466620937175. doi: 10.1177/1753466620937175.

24. Mardani R, Vasmehjani AA, Zali F, Gholami A, Nasab SDM, Kaghazian H, Kaviani M, Ahmadi N. Laboratory Parameters in Detection of COVID-19 Patients with Positive RT-PCR; a Diagnostic Accuracy Study. Arch Acad Emerg Med. 2020; 8(1):. PMC7130449.

25. Altın S, Sokucu SN, Fikri BI, Barça T, Toptaş EBM. Could ferritin level be an indicator of COVID-19 disease mortality? J Med Virol, 2020. https://doi.org/10.1002/jmv.26543.

26. Li C, Ye J, Chen Q, Hu W, Wang L, Fan Y, Lu Z, Chen J, et al. Elevated Lactate Dehydrogenase (LDH) level as an independent risk factor for the severity and mortality of COVID-19. Aging (Albany NY). 2020 Aug 14; 12(15): 15670-15681. doi: 10.18632/aging.103770.

27. Cheng B, Hu J, Zuo X, Chen J, Li X, Chen Y, Yang G, Shi X, Deng A. Predictors of progression from moderate to severe coronavirus disease 2019: a retrospective cohort. Clin Microbiol Infect. 2020 Oct; 26(10):1400-1405. doi: 10.1016/j.cmi.2020.06.033.

28. Tang N, Gando S, Falanga A, Cattaneo M, Levi M, Clark C, Iba T. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost, 2020. 18(5): 1023-1026. Available on: https://doi.org/10.1111/jth.14810.

29. Slimani H, Zhai Y, Yousif NG. et al. Enhanced monocyte chemotactrant protein-1 production in aging mice exaggerates cardiac depression during end toxemia. Crit Care. 18: S27, 2014. Available on: https://doi.org/10.1186/s13054-014-0527-8.

30. Serody JA, Russell KR, Chen R, Ferrara MB. Over expression of IL-Iβ- exaggerated myocardial injury after ischemia and reperfusion in mice model. American Journal of BioMedicine. 2021; 9(1): 110-122.

31. Sato M, Ma N, Zhang N. Over expression of S100P up-regulates cancer cell proliferation: unfavorable prognosis and tumor progression in patients with endometrial cancer. American Journal of BioMedicine. 2021; 9(1): 76-100.

32. Yousif NG. High-level of Notch1/JAG1 signaling pathway up regulated chemo-resistance of Bevacizumab in colon cancer: Inducing metastasis and poor survival. Annals of Oncology 2017; 28, iii86-iii87.

33. Masic I, Naser N, Zildzic M. Public Health Aspects of COVID-19 Infection with Focus on Cardiovascular Diseases. Mater Sociomed. 2020 Mar; 32(1): 71-76. doi: 10.5455/msm.202032.71-76.

34. Masic I, Gerc V. On Occasion of the COVID-19 Pandemic - One of the Most Important Dilemma : Vaccinate or Not? Med Arch. 2020 Jun; 74(2): 164-167. doi: 10.5455/medarh.2020.74.164-167.

35. Gerc V, Masic I, Salihefendic N, Zildzic M. Cardiovascular Diseases (CVDs) in COVID-19 Pandemic Era. Mater Sociomed. 2020 Jun; 74(2): 158-164. doi: 10.5455/medarh.2020.74.158-164.

36. Zildzic M, Masic I, Salihefendic N, Jasic M, Hajdarevic B. The Importance of Nutrition in Boosting Immunity for Prevention and Treatment COVID-19. Int J Biomed Healthc. 2020 Dec; 8: 73-79. doi: 10.5455/ijbh.2020.8.73-79.

37. Salihefendic Dz, Zildzic M, Masic I. The Importance of the Quantity and the Distribution Assessment of Fat Tissue in a Diagnosis of Insulin Resistance. Med Arch. 2020 Dec; 74(6): 439-443. doi: 10.5455/medarch.2020.74.439-443.

38. Karindas MM. The “Multicellular Origin” of Cancer and the Clonal Evolution of Oncogenesis. American Journal of Bio Medicine 2014; 2(2): 37-45.